Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Hims To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Hims between April 29, 2025 and June 23, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, June 28, 2025 (GLOBE NEWSWIRE) ...

I am receiving several questions from investors inquiring about this growth stock following its significant price decline.*Stock prices used were the afternoon prices of June 25, 2025. The video was published on June 27, 2025. ...

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws, following allegations of misrepresentation regarding a partnership with Novo Nordisk [1][2][4]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. - Two complaints have been filed, with the first case captioned Sookdeo v. Hims & Hers Health, Inc., and a subsequent similar complaint captioned Yaghsizian v. Hims & Hers Health, Inc. [2]. Group 2: Allegations Against Hims & Hers - Hims & Hers operates a telehealth platform providing access to healthcare consultations and wellness products, and recently announced a collaboration with Novo Nordisk to sell the weight loss drug Wegovy [3]. - Allegations include misrepresentation of the partnership with Novo Nordisk, claiming that Hims & Hers could offer both Wegovy and compounded semaglutide, and asserting compliance with FDA regulations [4]. Group 3: Stock Market Reaction - Following Novo Nordisk's announcement of terminating the partnership due to Hims & Hers' alleged deceptive practices, the stock price fell by $22.24 per share, a decline of over 34%, from $64.22 on June 20, 2025, to $41.98 on June 23, 2025 [5].

Hims & Hers (HIMS 6.81%) is attracting investors looking to buy the dip in this impressive growth stock.*Stock prices used were the afternoon prices of June 24, 2025. The video was published on June 26, 2025. ...

Core Viewpoint - Hims & Hers Health, Inc. is facing securities class action lawsuits due to allegations of failing to disclose material information during the class period, which has led to a significant drop in share price following a partnership termination announcement by Novo Nordisk [3][4]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to file lead plaintiff applications in the securities class action lawsuits against Hims, specifically for those who purchased securities between April 29, 2025, and June 23, 2025 [1]. - The lawsuits are pending in the United States District Court for the Northern District of California, with the first case being Sookdeo v. Hims & Hers Health, Inc. and a subsequent case expanding the class period [5]. Group 2: Company Impact - On June 23, 2025, Novo Nordisk announced the termination of its partnership with Hims, citing violations of laws regarding the sale of compounded drugs and concerns over patient safety due to potentially unsafe ingredients in products sold by Hims [4]. - Following this announcement, Hims' share price fell by $22.24, or 34.6%, closing at $41.98 per share on unusually heavy trading volume [4].

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. for alleged violations of federal securities laws during the Class Period from April 29, 2025, to June 23, 2025 [1][2]. Group 1: Allegations Against Hims & Hers - The lawsuit claims that Hims & Hers made materially false and misleading statements and failed to disclose adverse facts about its business and operations [3]. - Specific allegations include the deceptive promotion of illegitimate versions of Wegovy® that jeopardized patient safety, risking the termination of its collaboration with Novo Nordisk [3]. - The complaint also states that positive statements made by the company regarding its business prospects were misleading and lacked a reasonable basis [3]. Group 2: Details of Misleading Statements - Allegations include that Hims & Hers misrepresented its communication with Novo Nordisk, suggesting it would ensure continued access to Wegovy for subscribers [4]. - The complaint asserts that Novo approved Hims' offerings of compounded semaglutide products, which were falsely presented as compliant with regulations [4]. - Additionally, it is claimed that Hims & Hers made positive statements about the partnership with Novo and the availability of Wegovy alongside compounded products, which were misleading [4]. Group 3: Next Steps for Investors - Investors who suffered losses in Hims & Hers have until August 25, 2025, to request to be appointed as lead plaintiff in the class action [5]. - The law firm representing the investors operates on a contingency fee basis, meaning they will only collect fees if the case is successful [6].

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. concerning allegations of securities fraud and unlawful business practices [2][3]. Group 1: Lawsuit Details - The lawsuit involves claims that Hims & Hers and certain officers/directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Hims & Hers securities during the Class Period have until August 25, 2025, to request to be appointed as Lead Plaintiff [3]. Group 2: Partnership and Stock Impact - On April 29, 2025, Hims & Hers announced a collaboration with Novo Nordisk to sell a bundled offering of Wegovy® [3]. - On June 23, 2025, Novo Nordisk terminated its partnership with Hims & Hers, citing deceptive promotion and selling of illegitimate versions of Wegovy® that jeopardized patient safety [3]. - Following the termination announcement, Hims & Hers' stock price dropped by $22.24, or 34.63%, closing at $41.98 per share [3].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Hims & Hers Health, Inc. common stock during the specified Class Period, alleging misleading statements and failures to disclose critical information regarding partnerships and product offerings [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to common stock purchases of Hims & Hers Health, Inc. between April 29, 2025, and June 23, 2025 [1]. - The lawsuit claims that Hims made false and misleading statements about its collaboration with Novo Nordisk A/S, particularly regarding the availability of the weight-loss drug Wegovy and compounded semaglutide products [5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by August 25, 2025, to represent the class in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - The article emphasizes the importance of conducting personal due diligence before making investment decisions, highlighting that past performance does not guarantee future results [2][3]. Group 1 - The content is based on personal thoughts and research, and it is not intended as financial or investment advice [2][3]. - There is no business relationship with any company mentioned in the article, ensuring an unbiased perspective [1][2]. - The article acknowledges the potential for errors or misprints in the information provided, stressing the need for accuracy [2][3]. Group 2 - The article clarifies that the author does not hold any stock or derivative positions in the companies mentioned, which may influence the analysis [1]. - It is noted that the views expressed may not reflect those of the platform as a whole, indicating a diversity of opinions among contributors [3]. - The article serves as a reminder that all investments carry risks, including the possibility of total loss [2][3].

Core Viewpoint - Hims & Hers Health, Inc. is under investigation for potential securities fraud and unlawful business practices following the termination of its partnership with Novo Nordisk, which has raised concerns about patient safety and compliance with legal regulations [1][2]. Group 1: Company Developments - Novo Nordisk announced the discontinuation of its partnership with Hims & Hers, ending direct access to the Wegovy weight loss drug due to non-compliance with regulations regarding the sale of compounded drugs [2]. - Following the announcement, Hims & Hers' stock price experienced a significant decline, falling by $22.24 per share, or 34.63%, closing at $41.98 per share on June 23, 2025 [3]. Group 2: Legal and Regulatory Issues - Pomerantz LLP is investigating claims on behalf of investors regarding potential securities fraud or other unlawful business practices by Hims & Hers and its officers or directors [1].